ArticleBMC infectious diseases2025
Immunoglobulin glycosylation profiling for early identification of patients with severe influenza pneumonia.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundUncontrolled inflammation can result in severe status and even death in influenza patients, and there is a lack of early clinical evaluation models.
methodsWe recruited patients with influenza pneumonia and healthy controls from the emergency departments of three urban teaching hospitals in Beijing, China, during the winter of 2018-2019. Donated plasma samples were screened using protein and lectin microarrays to assess changes in the glycosylation patterns of immunoglobulins. These changes were used to develop and validate an Immunoglobulin Glycosylation Profile for Severe Status Identification Algorithm (IGPSSIA). A combined model of IGPSSIA score and clinical indicators was constructed to identify severe influenza pneumonia cases.
resultsWe enrolled 114 patients, including 56 in the mild and 58 in the severe groups, and recruited 27 volunteers as healthy controls. We screened out the differentially expressed glycan moieties between the mild and the severe groups and included them in the LASSO regression analysis. In the training set (70% of patients, n = 80), IGPSSIA = 1.113 × [GNL‑IgG4 Man] - 2.499 × [LCA‑IgG1 Man] + 0.029 × [BanLec‑IgA2 Man] + 0.529 × [HHL, AL‑IgM Man] - 2.210 × [sWGA‑IgG GlcNAc] + 0.001 × [PSA‑IgG4 Man] + 0.027 × [Ricin B Chain‑IgG2 Gal & GalNAc]. Finally, we constructed a clinical diagnostic model using age, time interval from onset to admission, lymphocyte count, platelet count and IGPSSIA score, and achieved an AUC of 0.839 (95% CI 0.767-0.911).
conclusionsChanges in immunoglobulin glycosylation profiles can be a promising tool for identifying severe status in patients with influenza pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.